Nieves Martinez Lago, Specialist in the Field (FEA) of Medical Oncology at University Hospital Complex of Santiago de Compostela, shared a post on X:
” Time toxicity in adv. BTC
1L GC ± durva, multicenter (n=193)
Median time toxicity: 14.4% of tx time
- Planned visits: 11.9%
- Unplanned: 1.8%
Durvalumab was associated with a longer treatment duration but a similar level of time toxicity.
Younger age and poor performance status were associated with increased time toxicity.”
Title: Time Toxicity in Patients With Advanced Biliary Tract Cancer Receiving Gemcitabine Plus Cisplatin With or Without Durvalumab
Authors: Naohiro Okano, Angelo Pirozzi, Conor O’Donnell, Masato Hayashi, Pedro Luiz Serrano Uson Junior, Celine Hoyek, Oluseyi Abidoye, Cody Eslinger, Binbin Zheng-Lin, Natalie M. Elliott, Elizabeth A. Raupach, Yumei Zhou, Joachim Petit, Daniel Ahn, Mohamad Bassam Sonbol, Christina Wu, Mariko Nishioka, Taro Sato, Maria Fernanda Teixeira, Isabella Sforzin, Hani M. Babiker, Umair Majeed, Nguyen H. Tran, Lorenza Rimassa, Fumio Nagashima, Shuichi Hironaka, Tanios Bekaii-Saab, Mitesh J. Borad
Read the Full Article.
Other articles featuring Nieves Martinez Lago.
